Merck's Gardasil vaccine crippled a young man - an ongoing medical tragedy that must be stopped
(Natural News) Robert F. Kennedy Jr. and the Baum Hedlund Law Firm from Los Angeles, California have filed their fifth lawsuit against Merck, taking on the drug company’s dangerous and deceptive Gardasil vaccine, and standing up for innocent young people who have been disabled by the vaccine. The law firm is taking on Merck and... (Source: NaturalNews.com)
Source: NaturalNews.com - January 26, 2021 Category: Consumer Health News Source Type: news

Merck discontinues development of possible COVID-19 vaccines following results
Kenilworth-based Merck has announced the company is discontinuing development of its COVID-19 vaccine candidates, V590 and V591. (Source: Reuters: Health)
Source: Reuters: Health - January 25, 2021 Category: Consumer Health News Source Type: news

Merck Ends Development of Two Potential COVID-19 Vaccines Merck Ends Development of Two Potential COVID-19 Vaccines
The drugmaker will stop developing two potential COVID-19 vaccines after seeing poor results in early-stage studies.Associated Press (Source: Medscape Medical News Headlines)
Source: Medscape Medical News Headlines - January 25, 2021 Category: Consumer Health News Tags: Infectious Diseases News Source Type: news

Merck abandons bid to develop Covid-19 vaccine
After lacklustre results, company says it will shift focus to potential drugs to treat the disease (Source: FT.com - Drugs and Healthcare)
Source: FT.com - Drugs and Healthcare - January 25, 2021 Category: Pharmaceuticals Source Type: news

Merck discontinues work on Covid-19 vaccine candidates
The company is continuing work on two therapeutics to treat coronavirus infections. (Source: bizjournals.com Health Care:Physician Practices headlines)
Source: bizjournals.com Health Care:Physician Practices headlines - January 25, 2021 Category: American Health Authors: John George Source Type: news

Covid live updates: Merck ends its vaccine development; Google offers its offices for vaccination sites
The U.S. is recording at least 170,000 new Covid-19 cases and at least 3,080 virus-related deaths each day, based on a seven-day average... (Source: Reuters: Health)
Source: Reuters: Health - January 25, 2021 Category: Consumer Health News Source Type: news

Merck ends development of two potential COVID-19 vaccines
Merck is giving up on two potential COVID-19 vaccines following poor results in early-stage studies (Source: ABC News: Health)
Source: ABC News: Health - January 25, 2021 Category: Consumer Health News Tags: Health Source Type: news

Merck Stops Developing Both Of Its COVID-19 Vaccine Candidates
Merck, which previously made an Ebola vaccine, had been seen as a serious contender in the worldwide race to come up with an answer to the coronavirus.(Image credit: Budrul Chukrut/SOPA Images/LightRocket via Getty Images) (Source: NPR Health and Science)
Source: NPR Health and Science - January 25, 2021 Category: Consumer Health News Authors: Bill Chappell Source Type: news

Merck Pulls The Plug On Covid-19 Vaccine Program After Disappointing Trial Data
The pharma heavyweight will now focus on developing two experimental Covid-19 drugs. (Source: Forbes.com Healthcare News)
Source: Forbes.com Healthcare News - January 25, 2021 Category: Pharmaceuticals Authors: Robert Hart, Forbes Staff Tags: Business /business Manufacturing /manufacturing Innovation /innovation Science /science Healthcare /healthcare Editors' Pick editors-pick Breaking breaking-news Coronavirus Source Type: news

Merck discontinues development of SARS-CoV-2/COVID-19 vaccine candidates; continues development of two investigational therapeutic candidates
Merck (NYSE: MRK), known as MSD outside the United States and Canada, today announced that the company is discontinuing development of its SARS-CoV-2/COVID-19 vaccine candidates, V590 and V591, and plans to focus its SARS-CoV-2/COVID-19 research strategy and production capabilities on advancing two therapeutic candidates, MK-4482 and MK-7110. (Source: World Pharma News)
Source: World Pharma News - January 25, 2021 Category: Pharmaceuticals Tags: Featured Merck Business and Industry Source Type: news

FDA Approves Verquvo (vericiguat) for Heart Failure with Reduced Ejection Fraction
KENILWORTH, N.J.--(BUSINESS WIRE)-- Merck (NYSE:MRK), known as MSD outside the United States and Canada, today announced that the U.S. Food and Drug Administration (FDA) has approved Verquvo, a soluble guanylate cyclase (sGC) stimulator, to reduce... (Source: Drugs.com - New Drug Approvals)
Source: Drugs.com - New Drug Approvals - January 20, 2021 Category: Drugs & Pharmacology Source Type: news

Philips and Merck partner to develop personalised fertility treatment
Remote patient monitoring, cloud-based platform services and AI-enabled ultrasound diagnoses will be used to improve outcomes in fertility treatment.   (Source: mobihealthnews)
Source: mobihealthnews - January 19, 2021 Category: Information Technology Source Type: news

WHO and Partners to Stockpile Ebola Vaccine
TUESDAY, Jan. 12, 2021 -- Ebola vaccines are being stockpiled by the World Health Organization and other groups to combat future outbreaks of the deadly disease. An emergency reserve of about 500,000 doses of a Merck vaccine will be established,... (Source: Drugs.com - Pharma News)
Source: Drugs.com - Pharma News - January 12, 2021 Category: Pharmaceuticals Source Type: news

Frazier Foundation donates $1M to help address social determinants of health in North Philadelphia
The American Heart Association said Tuesday it has received a $1 million gift from the Andr éa W. and Kenneth C. Frazier Family Foundation to support programs to address social factors that impact health care in North Philadelphia. Kenneth C. Frazier, a Philadelphia native, is the chairman and CEO of North Jersey-based pharmaceutical giant Merck (NYSE: MRK). Andréa Frazier is the founde r of the interior design firm Frazier Designs. The foundation's gift was made to the Heart Association’s Bernard… (Source: bizjournals.com Health Care:Physician Practices headlines)
Source: bizjournals.com Health Care:Physician Practices headlines - January 12, 2021 Category: American Health Authors: John George Source Type: news

Neil Young Sells Catalog Rights to Merck Mercuriadis ’s Hipgnosis
Hipgnosis founder Merck Mercuriadis, who bought Young’s publishing, promises fans that there will never be a “Burger of Gold” fast food... (Source: Reuters: Health)
Source: Reuters: Health - January 6, 2021 Category: Consumer Health News Source Type: news

Pfizer and BioNTech to Supply U.S. With Additional 100 Million Doses of COVID-19 Vaccine
(WASHINGTON) — Pfizer said Wednesday it will supply the U.S. government with an additional 100 million doses of its COVID-19 vaccine under a new agreement between the pharmaceutical giant and the Trump administration. Pfizer and its German partner BioNTech said that will bring their total current commitment to 200 million doses for the U.S. That should be enough to vaccinate 100 million people with the two-shot regimen. The government also has an option to purchase an additional 400 million doses. “This new federal purchase can give Americans even more confidence that we will have enough supply to vaccinate eve...
Source: TIME: Health - December 23, 2020 Category: Consumer Health News Authors: RICARDO ALONSO-ZALDIVAR / AP Tags: Uncategorized COVID-19 wire Source Type: news

Pfizer and BioNTech to Supply U.S. With Additional 100 Million Doses of COVID-19 Vaccine
(WASHINGTON) — Pfizer said Wednesday it will supply the U.S. government with an additional 100 million doses of its COVID-19 vaccine under a new agreement between the pharmaceutical giant and the Trump administration. Pfizer and its German partner BioNTech said that will bring their total current commitment to 200 million doses for the U.S. That should be enough to vaccinate 100 million people with the two-shot regimen. The government also has an option to purchase an additional 400 million doses. “This new federal purchase can give Americans even more confidence that we will have enough supply to vaccinate eve...
Source: TIME: Science - December 23, 2020 Category: Science Authors: RICARDO ALONSO-ZALDIVAR / AP Tags: Uncategorized COVID-19 wire Source Type: news

Uncorking the compliance bottlenecks in digital
Making compliance processes fit for the digital age quickly moved from being merely an important problem to a mission critical one this year. In the massive and almost overnight shift to digital engagement since pandemic lockdowns began, the demand for digital content has soared.  The marketeers ’ challenge of supplying content in the quantities and formats HCPs require just when they want it, is matched by the challenge of passing it all through the medical legal review (MLR) process that pharma was only beginning to reconfigure for the new digital realities before the pandemic struck. “MLR as a pro...
Source: EyeForPharma - December 17, 2020 Category: Pharmaceuticals Authors: Andrew Stone Source Type: news

Class 2 Medicines Recall: Merck Sharp & Dohme Limited, Zerbaxa 1g/0.5g Powder for Concentrate for Solution for Infusion
Merck Sharp& Dohme Limited is recalling specific batches of Zerbaxa 1g/0.5g Powder for Concentrate for Solution for Infusion as a precautionary measure due to the presence of Ralstonia pickettii (Source: Royal Pharmaceutical Society News)
Source: Royal Pharmaceutical Society News - December 17, 2020 Category: Drugs & Pharmacology Source Type: news

Merck plant where COVID-19 vaccines will be manufactured a "biohazard nightmare," production floor smeared with feces
(Natural News) Arie Menachem, a former U.S. Food and Drug Administration (FDA) quality control expert who used to inspect vaccine manufacturing plants, is blowing the whistle about the serious safety violations he says he observed at Merck & Co.’s jab production facilities. After being ignored by higher-ups at the FDA, Menachem went public to the... (Source: NaturalNews.com)
Source: NaturalNews.com - December 13, 2020 Category: Consumer Health News Source Type: news

BAVENCIO(R) (avelumab) Receives Positive CHMP Opinion for First-Line Maintenance Treatment of Locally Advanced or Metastatic Urothelial Carcinoma
ROCKLAND, Mass. and NEW YORK, Dec. 11, 2020 -- (Healthcare Sales & Marketing Network) -- EMD Serono, the biopharmaceutical business of Merck KGaA, Darmstadt, Germany in the US and Canada, and Pfizer Inc. (NYSE: PFE) today announced that the Committee for ... Biopharmaceuticals, Oncology, Regulatory EMD Serono, Merck KGaA, BAVENCIO, avelumab, Urothelial Carcinoma (Source: HSMN NewsFeed)
Source: HSMN NewsFeed - December 11, 2020 Category: Pharmaceuticals Source Type: news

Study: Immunotherapy Vaccine for Mesothelioma Still Promising
The ONCOS-102 immunotherapy vaccine continues its move toward future, first-line standard of care treatment for malignant pleural mesothelioma, based upon the latest study follow-up data. When combined with standard chemotherapy, the genetically modified adenovirus has produced a median overall survival of at least 18.2 months, according to results released in late November from the ongoing clinical trial. Median overall survival was more than four months better than the control group receiving chemotherapy alone in the randomized trial. ONCOS-102 is manufactured by Targovax, a small Scandinavian biotech company focused on...
Source: Asbestos and Mesothelioma News - December 3, 2020 Category: Environmental Health Authors: Fran Mannino Source Type: news

Merck KGaA, Darmstadt, Germany and Artios Pharma Announce a Global Strategic Collaboration on Novel DNA Damage Response Targets in Oncology
Merck KGaA, Darmstadt, Germany and Artios will conduct collaborative research and Merck KGaA, Darmstadt, Germany shall have the right to opt into exclusive development and commercialization of compounds on up to 8 targets Artios to receive US$30 million i... Biopharmaceuticals, Oncology Artios Pharma, Merck KGaA, DNA repair (Source: HSMN NewsFeed)
Source: HSMN NewsFeed - December 3, 2020 Category: Pharmaceuticals Source Type: news

UN Special Session on COVID-19 Must Recognize Right to Health & Access to Vaccines
A healthcare worker at a testing facility collects samples for the coronavirus at Mimar Sinan State Hospital, Buyukcekmece district in Istanbul, Turkey. Credit: UNDP Turkey/Levent KuluBy Riccardo PetrellaBRUSSELS, Nov 30 2020 (IPS) The holding of this Special Session (the 37th in the history of the UN) is of considerable importance. It is a unique opportunity to define and implement joint actions at the global level to fight the pandemic in order to ensure the right to life and health for all the inhabitants of the Earth. As the President of the UN General Assembly wrote in his letter of convocation: “Let us not forg...
Source: IPS Inter Press Service - Health - November 30, 2020 Category: International Medicine & Public Health Authors: Riccardo Petrella Tags: Development & Aid Education Featured Global Globalisation Headlines Health Inequity Poverty & SDGs TerraViva United Nations Source Type: news

MMR vaccine could protect against COVID-19
(American Society for Microbiology) The measles-mumps-rubella (MMR) vaccine has been theorized to provide protection against COVID-19. In a new study published inmBio, an open-access journal of the American Society for Microbiology, researchers provide further proof of this by showing that mumps IgG titers, or levels of IgG antibody, are inversely correlated with severity in recovered COVID-19 patients previously vaccinated with the MMR II vaccine produced by Merck (Source: EurekAlert! - Medicine and Health)
Source: EurekAlert! - Medicine and Health - November 20, 2020 Category: International Medicine & Public Health Source Type: news

Insights in the search for new antibiotics
(University of Oklahoma) A collaborative research team from the University of Oklahoma, the Memorial Sloan Kettering Cancer Center and Merck& Co. published an opinion article in the journal,Nature Chemical Biology, that addresses the gap in the discovery of new antibiotics. (Source: EurekAlert! - Biology)
Source: EurekAlert! - Biology - November 19, 2020 Category: Biology Source Type: news

Merck KGaA, Darmstadt, Germany to deploy Insilico Medicine's Chemistry42 AI platform
(InSilico Medicine) Insilico Medicine announces the first deployment of its flagship generative chemistry AI platform for de novo molecular design, Chemistry42 ™ on Merck KGaA, Darmstadt, Germany's high-performance computing infrastructure. (Source: EurekAlert! - Medicine and Health)
Source: EurekAlert! - Medicine and Health - November 17, 2020 Category: International Medicine & Public Health Source Type: news

RefleXion inks contract with proton therapy provider
Radiation therapy developer RefleXion Medical has announced a contract to provide...Read more on AuntMinnie.comRelated Reading: RefleXion to present at ASTRO 2020 RefleXion, Telix partner on high-risk cancer treatments RefleXion to collaborate with Merck on clinical trial RefleXion raises $100M in equity round RefleXion sells first X1 rad therapy machine (Source: AuntMinnie.com Headlines)
Source: AuntMinnie.com Headlines - November 16, 2020 Category: Radiology Source Type: news

FDA Approves Merck ’s Keytruda (pembrolizumab) in Combination With Chemotherapy for Patients With Locally Recurrent Unresectable or Metastatic Triple‑Negative Breast Cancer Whose Tumors Express PD-L1 (CPS ≥10)
KENILWORTH, N.J.--(BUSINESS WIRE) November 13, 2020 -- Merck (NYSE: MRK), known as MSD outside the United States and Canada, today announced that the U.S. Food and Drug Administration (FDA) has approved Keytruda, Merck’s anti-PD-1 therapy, in... (Source: Drugs.com - New Drug Approvals)
Source: Drugs.com - New Drug Approvals - November 13, 2020 Category: Drugs & Pharmacology Source Type: news

Holmusk & Merck partner to improve treatment outcomes for prediabetes & diabetes patients in APAC
The partnership will leverage on Holmusk ’s GlycoLeap platform to help patients achieve weight loss and improved blood glucose control.  (Source: mobihealthnews)
Source: mobihealthnews - November 11, 2020 Category: Information Technology Source Type: news

Malawi: First Lady Commits to Fight Infertility Stigma
[Nyasa Times] First Lady Monica Chakwera, who has been appointed as ambassador for the Merck Foundation's 'Merck More Than a Mother' initiative whose purpose is to build healthcare capacity and strengthen the response to COVID-19 in Africa, has stressed the need to amplify access to information, education and health in sensitising communities, especiall in rural areas, to understand infertility and break the stigma around barren women. (Source: AllAfrica News: Health and Medicine)
Source: AllAfrica News: Health and Medicine - October 28, 2020 Category: African Health Source Type: news

Merck Is Piloting A Drone Delivery Program For Medications
Although there are still many challenges and issues to be resolved with this area of technology, it may potentially be a way to one day address critical access-to-care issues. (Source: Forbes.com Healthcare News)
Source: Forbes.com Healthcare News - October 27, 2020 Category: Pharmaceuticals Authors: Sai Balasubramanian, J.D., Contributor Tags: Healthcare /healthcare Innovation /innovation Business /business Source Type: news

RefleXion to present at ASTRO 2020
Radiation therapy equipment developer RefleXion Medical announced that seven...Read more on AuntMinnie.comRelated Reading: RefleXion, Telix partner on high-risk cancer treatments RefleXion to collaborate with Merck on clinical trial RefleXion raises $100M in equity round RefleXion sells first X1 rad therapy machine RefleXion gets FDA nod for rad therapy (Source: AuntMinnie.com Headlines)
Source: AuntMinnie.com Headlines - October 23, 2020 Category: Radiology Source Type: news

IAVI, Merck KGaA, Serum Institute join hands to develop monoclonal antibodies for Covid-19
A phase-I clinical trial is expected to start in early 2021. (Source: The Economic Times Healthcare and Biotech News)
Source: The Economic Times Healthcare and Biotech News - October 22, 2020 Category: Pharmaceuticals Source Type: news

How are Personality Disorders Clustered?
Discussion Personality traits (PT) represent patterns of thinking, perceiving, reacting, and relating that are relatively stable over time. There are 5 major PT: Extraversion (e.g. tendency to be sociable) Neuroticism (e.g. susceptibility to negative thoughts and distress) Conscientiousness (e.g. self-regulation and being able to look at long term goals) Agreeableness (e.g. self-regulations and relationship maintenance) Openness to experience (e.g. imaginative, creative, curiosity). Personality disorders (PD) occur when these personality traits become so conspicuous, rigid and maladaptive that they cause impairment in ...
Source: PediatricEducation.org - October 19, 2020 Category: Pediatrics Authors: Pediatric Education Tags: Uncategorized Source Type: news

FDA Approves Expanded Indication for Merck ’s Keytruda (pembrolizumab) in Adult Patients With Relapsed or Refractory Classical Hodgkin Lymphoma (cHL)
KENILWORTH, N.J.--(BUSINESS WIRE) October 15, 2020 -- Merck (NYSE:MRK), known as MSD outside the United States and Canada, today announced that the U.S. Food and Drug Administration (FDA) has approved an expanded label for Keytruda, Merck’s... (Source: Drugs.com - New Drug Approvals)
Source: Drugs.com - New Drug Approvals - October 15, 2020 Category: Drugs & Pharmacology Source Type: news

Merck CEO Ken Frazier Calls On Corporate America To Help Stabilize Society
Frazier says companies should lobby for better education, healthcare and social justice, just like they lobby for business interests. (Source: Forbes.com Healthcare News)
Source: Forbes.com Healthcare News - October 14, 2020 Category: Pharmaceuticals Authors: Katie Jennings, Forbes Staff Tags: Healthcare /healthcare Innovation /innovation Business /business Editors' Pick editors-pick Coronavirus Decision Maker Content decisionmaker Source Type: news

Zimbabwe: 100 Doctors to Undergo Further Training in India
[263Chat] A total of 100 doctors will undergo training for different medical fields under the First Lady Auxillia Mnangagwa's Initiative in collaboration with Merck Foundations. (Source: AllAfrica News: Health and Medicine)
Source: AllAfrica News: Health and Medicine - September 30, 2020 Category: African Health Source Type: news

Seattle Genetics plans manufacturing expansion with cash from Merck deal
The biotech firm already has a 51,000-square-foot manufacturing site in Bothell. Its next one could be two or three times the size. (Source: bizjournals.com Health Care:Biotechnology headlines)
Source: bizjournals.com Health Care:Biotechnology headlines - September 17, 2020 Category: Biotechnology Authors: Megan Campbell Source Type: news

Seattle Genetics strikes potential $4.2B deal for breast cancer drug
Seattle Genetics announced Monday a deal with New Jersey-based Merck& Co. Inc. to globally develop a drug that targets breast cancer and other solid tumors currently in Phase 2 trials. Merck will pay $600 million upfront and make a $1 billion equity investment in 5 million shares of Seattle Genetics’ common stock at a price of $200 per share. Additionally, Seattle Genetics is eligible for progress-dependent milestone payments of up to $2.6 billion, including $850 million in de velopment milestones… (Source: bizjournals.com Health Care:Biotechnology headlines)
Source: bizjournals.com Health Care:Biotechnology headlines - September 14, 2020 Category: Biotechnology Authors: Megan Campbell Source Type: news

Seattle Genetics strikes potential $4.2B deal for breast cancer drug
Seattle Genetics announced Monday a deal with New Jersey-based Merck& Co. Inc. to globally develop a drug that targets breast cancer and other solid tumors. The drug is currently in Phase 2 trials. Merck will pay $600 million upfront and make a $1 billion equity investment in 5 million shares of Seattle Genetics’ common stock at a price of $200 per share. Additionally, Seattle Genetics is eligible for progress-dependent milestone payments of up to $2.6 billion, including $850 million in de velopment… (Source: bizjournals.com Health Care:Pharmaceuticals headlines)
Source: bizjournals.com Health Care:Pharmaceuticals headlines - September 14, 2020 Category: Pharmaceuticals Authors: Megan Campbell Source Type: news

Robot dogs take on routine tasks at Germany’s Merck
Pharmaceutical group employs services of Spot to carry out checks at incineration plants (Source: FT.com - Drugs and Healthcare)
Source: FT.com - Drugs and Healthcare - September 14, 2020 Category: Pharmaceuticals Source Type: news

Coronavirus Vaccine: 9 Drug Companies Pledge to ‘Stand With Science’
The joint statement by competitors was seen as an effort to restore public trust as President Trump has pushed for a vaccine before the presidential election. (Source: NYT Health)
Source: NYT Health - September 8, 2020 Category: Consumer Health News Authors: Katie Thomas Tags: Clinical Trials Vaccination and Immunization Coronavirus (2019-nCoV) AstraZeneca PLC Food and Drug Administration GlaxoSmithKline PLC Johnson & Merck Company Inc Moderna Inc Novavax Inc Pfizer Inc Sanofi SA Trump, Donald J Bo Source Type: news

Biopharma Leaders Unite To Stand With Science
NEW YORK, September 8, 2020 — The CEOs of AstraZeneca (LSE/STO/NYSE: AZN), BioNTech (NASDAQ: BNTX), GlaxoSmithKline plc (LSE/NYSE: GSK), Johnson & Johnson (NYSE: JNJ), Merck (NYSE: MRK), known as MSD outside the United States and Canada, Moderna, Inc. (Nasdaq: MRNA), Novavax, Inc. (Nasdaq: NVAX), Pfizer Inc. (NYSE: PFE), and Sanofi (NASDAQ: SNY), today announced a historic pledge, outlining a united commitment to uphold the integrity of the scientific process as they work towards potential global regulatory filings and approvals of the first COVID-19 vaccines. All nine CEOs signed the following pledge: We, the un...
Source: Johnson and Johnson - September 8, 2020 Category: Pharmaceuticals Tags: Our Company Source Type: news

Biopharma leaders unite to stand with science
The CEOs of AstraZeneca (LSE/STO/NYSE: AZN), BioNTech (NASDAQ: BNTX), GlaxoSmithKline plc (LSE/NYSE: GSK), Johnson & Johnson (NYSE: JNJ), Merck (NYSE: MRK), known as MSD outside the United States and Canada, Moderna, Inc. (Nasdaq: MRNA), Novavax, Inc. (Nasdaq: NVAX), Pfizer Inc. (NYSE: PFE), and Sanofi (NASDAQ: SNY), today announced a historic pledge, outlining a united commitment to uphold the integrity of the scientific process as they work towards potential global regulatory filings and approvals of the first COVID-19 vaccines. (Source: World Pharma News)
Source: World Pharma News - September 8, 2020 Category: Pharmaceuticals Tags: Featured AstraZeneca Business and Industry Source Type: news

FDA Accepts Filing of New Drug Application for Tepotinib for the Treatment of Patients with Metastatic NSCLC with METex14 Skipping Alterations
Tepotinib granted Priority Review and is being evaluated under FDA Real-Time Oncology Review (RTOR) pilot program Tepotinib is a highly targeted inhibitor of c-MET that is administered as a once-daily oral tablet Data show robust, consistent and dura... Biopharmaceuticals, Oncology, FDA EMD Serono, Merck KGaA, Tepotinib, NSCLC (Source: HSMN NewsFeed)
Source: HSMN NewsFeed - August 25, 2020 Category: Pharmaceuticals Source Type: news

FDA Accepts Filing of New Drug Application for Tepotinib for the Treatment of Patients with Metastatic NSCLC with METex14 Skipping Alterations
ROCKLAND, Mass., Aug. 25, 2020 /PRNewswire/ -- EMD Serono, the biopharmaceutical business of Merck KGaA, Darmstadt, Germany in the US and Canada, today announced that the US Food and Drug Administration (FDA) has... (Source: Drugs.com - New Drug Applications)
Source: Drugs.com - New Drug Applications - August 25, 2020 Category: Drugs & Pharmacology Source Type: news

New Lung Cancer Trial Could Benefit Mesothelioma Patients
Pharmaceutical giant Merck has teamed up with Novocure to test its cornerstone immunotherapy, pembrolizumab (Keytruda), alongside Tumor Treating Fields. The new phase II clinical research trial is focusing on non-small cell lung cancer and will enroll approximately 66 patients across the U.S. Keytruda, Merck’s anti-PD-1 therapy, works as a checkpoint inhibitor and allows the immune system to identify and attack cancer cells hiding within the PD-1 pathway. The FDA approved Keytruda for mesothelioma as the first immunotherapy treatment for the disease in 2020. Novocure, a global oncology company, has been developing...
Source: Asbestos and Mesothelioma News - August 19, 2020 Category: Environmental Health Authors: Fran Mannino Source Type: news

Merck plans to build £1bn UK research hub in central London
US pharma group says Britain is ‘world leader’ in developing science (Source: FT.com - Drugs and Healthcare)
Source: FT.com - Drugs and Healthcare - August 18, 2020 Category: Pharmaceuticals Source Type: news

Merck, Targovax Team Up for New Mesothelioma Clinical Trial
Standard-of-care treatment for malignant mesothelioma could change significantly, depending upon the results of an upcoming clinical trial of two immunotherapy agents used in combination with chemotherapy. The mesothelioma clinical trial will involve pembrolizumab, also known by the brand name Keytruda, and its synergy with ONCOS-102, a lesser-known, genetically modified adenovirus. Individually, both have shown modest efficacy for mesothelioma patients when used with chemotherapy. Together, there is potential for a much greater impact in significantly extending patient survival. The clinical trial is a partnership between...
Source: Asbestos and Mesothelioma News - July 22, 2020 Category: Environmental Health Authors: Fran Mannino Source Type: news